<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03321981</url>
  </required_header>
  <id_info>
    <org_study_id>MCLA-128-CL02</org_study_id>
    <secondary_id>2017-002821-39</secondary_id>
    <nct_id>NCT03321981</nct_id>
  </id_info>
  <brief_title>MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer</brief_title>
  <official_title>Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merus N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merus N.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, open-label, multicenter international study will be performed to evaluate the&#xD;
      efficacy of MCLA-128-based combinations. Three combination treatments will be evaluated, two&#xD;
      in Cohort 1 and one in Cohort 2.&#xD;
&#xD;
      MCLA-128 is given in combinations in two metastatic breast cancer (MBC) populations,&#xD;
      HER2-positive/amplified (Cohort 1) and Estrogen Receptor-positive/low HER2 expression&#xD;
      (Cohort2).&#xD;
&#xD;
      Two combinations treatments will be evaluated in Cohort 1, the doublet and triplet. Initially&#xD;
      MCLA-128 is given in combination with trastuzumab in the doublet. After the safety of the&#xD;
      doublet has been assessed in 4-6 patients, MCLA-128 is given in combination with trastuzumab&#xD;
      and vinorelbine in the triplet, in parallel to the efficacy expansion of the doublet.&#xD;
&#xD;
      The doublet and triplet combinations are both evaluated in two steps with an initial safety&#xD;
      run-in followed by a cohort efficacy expansion. In total up to 40 patients evaluable for&#xD;
      efficacy are included in both the doublet and triplet.&#xD;
&#xD;
      In Cohort 2 MCLA-128 is administered in combination with the same previous endocrine therapy&#xD;
      on which progressive disease is radiologically documented. A total of up to 40 patients&#xD;
      evaluable for efficacy are included in the Cohort 2.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>three combination treatments will be evaluated, two in Cohort 1 and one in Cohort 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate at 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of patients with a best overall response of Complete Response, Partial Response or Stable Disease at 24 weeks based upon RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the time from treatment start until radiologic progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the proportion of patients with overall response of Complete Response or Partial Response based upon RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline, every 6 weeks until progression up to one year after last patient first treatment</time_frame>
    <description>the time from response (Complete Response or Partial Response) until progression or death due to underlying cancer based upon RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 3 months after last visit up to 1 year after last patient first treatment</time_frame>
    <description>the time from treatment start until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with treatment emergent Adverse Events (AE)</measure>
    <time_frame>continuous until 1 year after last patient last treatment</time_frame>
    <description>Evaluation of number of participants with Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients that discontinue due to intolerability of study drug</measure>
    <time_frame>continuous through study completion, an average of 6 months</time_frame>
    <description>discontinuations due to AEs, dose modifications due to AEs and immunogenicity assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration [Cmax]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>maximum plasma concentration [Cmax] for MCLA-128 as measured from all individual plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough plasma concentration [C0h]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>plasma concentration of MCLA-128 as measured at trough level t=0h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve [AUC]</measure>
    <time_frame>baseline and 3-12 weeks until last patient last treatment</time_frame>
    <description>area under the concentration curve [AUC] for MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clearance [CL]</measure>
    <time_frame>6 weeks</time_frame>
    <description>clearance [CL] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>volume of distribution at steady state [Vss]</measure>
    <time_frame>6 weeks</time_frame>
    <description>volume of distribution at steady state [Vss] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum concentration [tmax]</measure>
    <time_frame>6 weeks</time_frame>
    <description>time to reach maximum concentration [tmax] for MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half life [t1/2]</measure>
    <time_frame>6 weeks</time_frame>
    <description>half life [t1/2] of MCLA-128</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of trastuzumab at end of infusion [C EOI]</measure>
    <time_frame>6 weeks</time_frame>
    <description>concentration of trastuzumab at end of infusion [C EOI]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>trough plasma concentration [C0h] trastuzumab</measure>
    <time_frame>6 weeks</time_frame>
    <description>plasma concentration of trastuzumab as measured at trough level t=0h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-drug antibodies serum titers</measure>
    <time_frame>baseline and 6-12 weeks until last patient last treatment</time_frame>
    <description>serum titers of anti-drug antibodies against MCLA-128</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Breast Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCLA-128</intervention_name>
    <description>full length IgG1 bispecific antibody targeting HER2 and HER3</description>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>bispecific</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>humanised IgG1 monoclonal antibody</description>
    <arm_group_label>Cohort 1 doublet</arm_group_label>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>antineoplastic drug of vinca alkaloid family</description>
    <arm_group_label>Cohort 1 triplet</arm_group_label>
    <other_name>Navelbine</other_name>
    <other_name>vinorelbine tartrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>same endocrine therapy is administered as the last line of endocrine therapy</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>fulvestrant</other_name>
    <other_name>exemestane</other_name>
    <other_name>letrozole</other_name>
    <other_name>anastrazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent before initiation of any study procedures.&#xD;
&#xD;
          2. Women with histologically or cytologically confirmed breast cancer with evidence of&#xD;
             metastatic or locally advanced disease not amenable to any local therapy with curative&#xD;
             intent.&#xD;
&#xD;
          3. Measurable disease as defined by RECIST version 1.1 by radiologic methods on or after&#xD;
             the most recent line of therapy. For Cohort 2 patients with bone-only disease are&#xD;
             eligible even in absence of measurable disease and must have lytic or mixed lesions.&#xD;
             For Cohort 2, imaging must be available for central review.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status of 0 or 1.&#xD;
&#xD;
          5. Life expectancy of ≥ 12 weeks, as per investigator.&#xD;
&#xD;
          6. Left ventricular ejection fraction ≥ 50% by echocardiogram or multiple gated&#xD;
             acquisition scan.&#xD;
&#xD;
          7. Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system metastases that are untreated or symptomatic, or require&#xD;
             radiation, surgery, or continued steroid therapy to control symptoms within 14 days of&#xD;
             study entry.&#xD;
&#xD;
          2. Known leptomeningeal involvement.&#xD;
&#xD;
          3. Advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening&#xD;
             complications in the short term.&#xD;
&#xD;
          4. Participation in another interventional clinical trial or treatment with any&#xD;
             investigational drug within 4 weeks prior to study entry.&#xD;
&#xD;
          5. Any systemic anticancer therapy within 3 weeks of the first dose of study treatment.&#xD;
             For cytotoxic agents that have major delayed toxicity a washout period of 6 weeks is&#xD;
             required. For patients in Cohort 2, this does not apply to the most recently received&#xD;
             hormone therapy.&#xD;
&#xD;
          6. Major surgery or radiotherapy within 3 weeks of the first dose of study treatment.&#xD;
             Patients who received prior radiotherapy to ≥ 25% of bone marrow are not eligible,&#xD;
             irrespective of when it was received.&#xD;
&#xD;
          7. Persistent grade &gt; 1 clinically significant toxicities related to prior antineoplastic&#xD;
             therapies (except for alopecia); stable sensory neuropathy ≤ grade 1 NCI-CTCAE v. 4.03&#xD;
             is allowed.&#xD;
&#xD;
          8. History of hypersensitivity reaction or any toxicity attributed to trastuzumab or&#xD;
             murine proteins that warranted permanent cessation of these agents (applicable for&#xD;
             Cohort 1 only).&#xD;
&#xD;
          9. Previous exposure to vinorelbine (applicable for Cohort 1 triplet combination only)&#xD;
&#xD;
         10. Exposure to specific cumulative anthracycline doses&#xD;
&#xD;
         11. Chronic use of high-dose oral corticosteroid therapy .&#xD;
&#xD;
         12. Uncontrolled hypertension or unstable angina.&#xD;
&#xD;
         13. History of congestive heart failure of Class II-IV New York Heart Association (NYHA)&#xD;
             criteria, or serious cardiac arrhythmia requiring treatment (except atrial&#xD;
             fibrillation, paroxysmal supraventricular tachycardia).&#xD;
&#xD;
         14. History of myocardial infarction within 6 months of study entry.&#xD;
&#xD;
         15. History of prior or concomitant malignancies (other than excised non-melanoma skin&#xD;
             cancer or cured in situ cervical carcinoma) within 3 years of study entry.&#xD;
&#xD;
         16. Current dyspnea at rest of any origin, or other diseases requiring continuous oxygen&#xD;
             therapy.&#xD;
&#xD;
         17. Current serious illness or medical conditions including, but not limited to&#xD;
             uncontrolled active infection, clinically significant pulmonary, metabolic or&#xD;
             psychiatric disorders.&#xD;
&#xD;
         18. Known HIV, HBV, or HCV infection.&#xD;
&#xD;
         19. Pregnant or lactating women; women of childbearing potential must use effective&#xD;
             contraception methods prior to study entry, for the duration of study participation,&#xD;
             and for 6 months after the last dose of MCLA-128.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director: Ernesto Wasserman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merus N.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Chattanooga</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi (GHdC)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute NKI</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Champalimaud Clinical Centre</name>
      <address>
        <city>Lisbon</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopistal San Antonio</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português Oncologia</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall D'Hebron Institute of Oncology (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic. C/Villaroel</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramon Y Cajal Universitary Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bispecific Antibody IgG1, HER2 HER3</keyword>
  <keyword>MCLA-128</keyword>
  <keyword>Antibodies, bispecific</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Cytokines</keyword>
  <keyword>combination Trastuzumab with and without Vinorelbine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

